CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
Rifabutindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002032
NCT00002032N/ACompleted
CompareCT.gov

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Pharmacia·interventional·Posted Aug 31, 2001·Updated Jun 24, 2005

In Brief

A clinical study evaluating Rifabutin for Mycobacterium Avium-intracellulare Infection and HIV Infections. Completed, across 33 sites.

Detailed Summary

The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200 cells/mm3. To investigate the incidence of MAC in these patients. A secondary objective is to compare clinical response, quality of life (Karnofsky), and survival between these two groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMycobacterium Avium-intracellulare Infection, HIV Infections
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Rifabutindrug